Secukinumab: Frequently Asked Questions Answered
What is secukinumab?
Secukinumab is a fully human IgG1κ monoclonal antibody (biological medicine) used to treat inflammatory diseases in humans. Secukinumab was approved in January 2015 in the United States and in the European Union to treat adults with moderate-to-severe plaque psoriasis. Secukinumab is branded and sold as Cosentyx by Novartis. Secukinumab binds to the protein interleukin-17A and inhibits its action. Cosentyx is used to treat psoriasis, ankylosing spondylitis and psoriatic arthritis.
What are the uses of Secukinumab?
Secukinumab is used for treating the following conditions:
- Plaque psoriasis (a skin disease with raised red patches covered with a whitish buildup of dead skin cells)
- Psoriatic arthritis (a type of inflammatory arthritis with symptoms such as joint pain, stiffness and swelling)
- Ankylosing spondylitis (inflammatory arthritis affecting the spine and large joints)
- Axial spondyloarthritis (a chronic inflammatory rheumatic disease that affects the axial bones, causing stiffness, severe pain and fatigue)